Lumen Bioscience raises $16M Series B to scale Spirulina platform for orally delivered antibodies; total funding $68M

Lumen Bioscience raised $16 million in a Series B to advance its Spirulina-based platform that produces orally delivered antibodies and biologics for GI diseases, claiming dramatically lower costs and three clinical programs. The Seattle startup, co‑founded in 2017 by CEO Brian Finrow and CSO Jim Roberts, has partnerships with the Gates Foundation, NIH and others and has raised $68 million to date.

AA-Alpha Bio LLumen Biosciences FFred Hutch Cancer Center